---
title: "Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286864557.md"
description: "Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News"
datetime: "2026-05-18T22:30:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286864557.md)
  - [en](https://longbridge.com/en/news/286864557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286864557.md)
---

# Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

### Related Stocks

- [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md)
- [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md)

## Related News & Research

- [Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement | BAYRY Stock News](https://longbridge.com/en/news/286570938.md)
- [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md)
- [Class action lawyers seek $675 million in Bayer Roundup settlement](https://longbridge.com/en/news/286161918.md)
- [Bayer agrees to pay $133 million for PCB cleanup in two states](https://longbridge.com/en/news/286810928.md)
- [Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline](https://longbridge.com/en/news/285889049.md)